Iterative Health vs Triomics
Two companies sitting between clinical care and clinical research, reached from opposite directions. Iterative started with computer vision on the colonoscopy feed and has moved decisively toward research acceleration, so a buyer today is engaging with a research organisation that also has a device. Triomics started with the chart, is oncology tuned, holds peer reviewed validation and traces every match back to the pathology and biomarker behind it, delivered where the oncology team already works. For a gastroenterology unit wanting detection, Iterative's shift in emphasis is the thing to weigh, because support and roadmap follow attention. For a cancer centre wanting more patients into trials, Triomics does the eligibility reasoning and Iterative brings the network.
- The detection device sits between the scope and the monitor performing local inference, and the company has shifted decisively toward clinical research alongside it.
- For a health system interested in trial participation as well as detection, the research network is the larger part of what is on offer.
- Gastroenterology is the shared specialty, so a unit evaluating both is comparing within its own service line.
- It is oncology tuned chart abstraction with peer reviewed validation in a recognised journal, tracing every match to the pathology and biomarker that produced it.
- The output lands where the oncology team already works rather than in a separate research tool.
- For a cancer centre, the eligibility reasoning is the constraint rather than the procedure itself.
Side by Side
| Axis | I Iterative Health |
T Triomics |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These are compared because both sit between a clinical service and a research programme, not because a buyer chooses one over the other. Read the corporate direction on Iterative carefully: the company now presents primarily as a clinical research organisation with its detection device relegated in its own materials, which changes what a purchaser is committing to and how the device is likely to be supported. Neither publishes a false negative rate for the patients its process does not surface, and neither publishes pricing.